Trends & Forecasts

EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.

Trump signs executive order on lowering drug prices and amends Medicare price negotiation for small molecule drugs.

The political situation in the US and its impact on science and medicine is changing rapidly. Here’s a quick look at the latest developments.

We dive into the archive of 2022 for insight and inspiration – this time with Kowid Ho

Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry?

We ask James Chambers from Tufts Medical Center about the challenges faced by biosimilars in the US.

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems; we ask experts about the future of advanced medicine.

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track

Why the ability to design therapeutics based on glycobiology will make a mark on pharma R&D.

Thoughts on the US National Institutes of Health and its role in funding research for non-opioid therapeutics.